US Court Rules Again That Natural Phenomena Cannot Be Patented, Casting Further Doubt On Gene Patents

from the keep-'em-coming dept

Back in June, Mike wrote about the important Myriad Genetics judgment from the Supreme Court, which said that naturally-occuring genetic material could not be patented. However, because of some hedging from the judges, there were concerns about how much this would block gene patents in practice. Last week we had an indication that the impact is indeed likely to be significant, as VentureBeat reports:

a District Court judge in California upheld the landmark [SCOTUS] ruling, and struck down a patent held by a San Diego-based diagnostics company called Sequenom. Sequenom offers a non-invasive genetic test for Down's Syndrome, which pregnant women can take as early as 10 weeks.

Sequenom plans to appeal the decision to the Federal Circuit Court of Appeals. It was highly unexpected, and has caused shockwaves of disbelief in the scientific community. The judge, Susan Illston of the United States District Court in Northern California, ruled against Sequenom after a summary judgement, citing the Supreme Court case "Association for Molecular Pathology v. Myriad Genetics, Inc., 12-398."

In both cases, the judge ruled that a "natural phenomenon" could not be patented.
As Science magazine explained in its report on the case:
If this decision stands, "I don’t see how you can maintain a genetic diagnostic claim anymore," says Christopher Holman, a molecular biologist and professor of law at the University of Missouri, Kansas City.
However, that does not mean that biotech is now an area that will be abandoned by investors. As the VentureBeat story notes:
Bryan Roberts, a health-focused investment partner at Venrock, predicts that "real innovation will be patentable and rewarded" while patents on natural phenomena will not. Roberts is a leading investor in Ariosa Diagnostics, the San Jose, Calif. based company that filed suit against Sequenom in 2011.
That connection means that Roberts may be biased in his view of this particular case, but his broader analysis of the ruling's impact remains true:
The ruling "raises the bar to rely on intellectual property as a business defense," said Roberts. "It will drive prices down [and support] the product that is both high quality and efficiently priced."
What makes this latest judgement (embedded below) particularly welcome is that it joins the Myriad Genetics decision, and an earlier SCOTUS ruling that struck down a patent on basic medical diagnostics, to form part of a growing body of US case law that brings some much-needed sanity to the world of gene patents.

Follow me @glynmoody on Twitter or, and +glynmoody on Google+

Filed Under: biotech, dna, gene patents, patents
Companies: ariosa diagnostics, myriad genetics, sequenom

Reader Comments

Subscribe: RSS

View by: Time | Thread

  1. identicon
    PopeyeLePoteaux, 5 Nov 2013 @ 1:56pm

    Re: A simple fix for this whole mess

    Or what we know as corporate bribing or lobbying.

Add Your Comment

Have a Techdirt Account? Sign in now. Want one? Register here

Subscribe to the Techdirt Daily newsletter

Comment Options:

  • Use markdown. Use plain text.
  • Remember name/email/url (set a cookie)

Follow Techdirt
Special Affiliate Offer

Report this ad  |  Hide Techdirt ads
Essential Reading
Techdirt Deals
Report this ad  |  Hide Techdirt ads
Techdirt Insider Chat
Report this ad  |  Hide Techdirt ads
Recent Stories
Report this ad  |  Hide Techdirt ads


Email This

This feature is only available to registered users. Register or sign in to use it.